Racial/ethnic, age and sex disparities in leukemia survival among adults in the United States during 1973-2014 period
Date
2019-08-19Author
Utuama, Ovie
Mukhtar, Fahad
Pham, Yen Thi-Hai
Dabo, Bashir
Manani, Priyashi
Moser, Jenna
Michael-Asalu, Abimbola
Tran, Chi TD
Le, Linh C.
Le, Thanh V.
Vu, Khanh Truong
Park, Jong Y.
Boffetta, Paolo
Zheng, Wei
Shu, Xiao-Ou
Luu, Hung N.
Metadata
Show full item recordAbstract
There has been marked improvement in leukemia survival, particularly among children in recent time. However, the long-term trends in survival among adult leukemia patients and the associated sex and racial survival disparities are not well understood. We, therefore, evaluated the secular trends in survival improvement of leukemia patients from 1973 through 2014, using Surveillance Epidemiology and End-Result Survey Program (SEER) data. ICD-O-3 morphology codes were used to group leukemia into four types: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML). Survival analysis for each leukemia type stratified by race/ethnicity, age, sex was performed to generate relative survival probability estimates for the baseline time period of 1973 through 1979. Hazard ratios (HR) and respective 95% confidence intervals (CIs) for survival within subsequent 10-year time periods by race, age and sex were calculated using Cox proportional hazard models. Of the 83,255 leukemia patients for the current analysis, the 5-year survival of patients with ALL, AML, CLL, and CML during 1973–1979 were 42.0%, 6.5%, 66.5%, and 20.9%, respectively. Compared to the baseline, there were substantial improvements of leukemia-specific survival in 2010–2014 among African-American (81.0%) and Asian (80.0%) patients with CML and among 20–49 year of age with CLL (96.0%). African-American patients, those with AML and those older than 75 years of age had the lowest survival improvements. Asians experienced some of the largest survival improvements during the study period. Others, including African-American and the elderly, have not benefited as much from advances in leukemia treatment.
Collections
- Le Cu Linh, MD, PhD [12]